Real-world treatment patterns and outcomes in advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma treated with first-line anti-HER2 therapy in England

Background: This study aimed to examine real-world treatment patterns and outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma receiving anticancer therapy in England. Methods: Using the Cancer Analys...

Full description

Bibliographic Details

Published in:	ESMO Gastrointestinal Oncology
Main Authors:	N. Starling, L. Zhang, K. Dunton, A. Strübing, Y. Xiong, C. Livings, L. Brannman, M.Y. Beykloo, H. Mohamed, N. Trankov, P. Egger
Format:	Article
Language:	English
Published:	Elsevier 2025-12-01
Subjects:	anti-HER2 therapy gastric cancer gastroesophageal junction adenocarcinoma HER2 trastuzumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949819825001116